Health In Tech, Inc. filings document material-event disclosures for a Nevada operating company with Class A common stock listed on the Nasdaq Capital Market under HIT. Recent Form 8-K reports cover results of operations and financial condition, Regulation FD materials, investor presentations and conference-call transcripts.
The filing record also addresses capital-structure matters, including a private investment in public equity financing, and governance disclosures involving executive officer departures, compensatory arrangements and related consulting agreements. The company identifies as an emerging growth company in its Exchange Act reports.
Health In Tech, Inc. reports Q1 2026 results with total revenue of $8,771,646 and a net loss of $1,588,281, compared with net income in the prior-year quarter. Revenue grew mainly from fees, while underwriting modeling revenue declined.
Cost of revenues and operating expenses rose sharply, driven by higher sales and marketing, research and development, and amortization of capitalized software, compressing gross profit to $4,509,399. The company strengthened liquidity through a March 2026 PIPE, issuing 5,600,000 Class A shares at $1.25 per share for net proceeds of $6,381,000, lifting cash and cash equivalents to $10,325,208 at quarter end.
Health In Tech, Inc. reported first quarter 2026 revenue of $8.8 million, up about 9% year over year, as it shifts into an investment phase to support long-term growth. The company introduced new metrics to better explain its recurring business model and revenue visibility.
As of March 31, 2026, Contracted Revenue expected to be recognized over the remaining three quarters of 2026 was about $22.9 million, and first-quarter Platform Placed Plan Value reached $82 million in self-funded stop-loss plans placed through its platform. Management is reiterating full-year 2026 revenue guidance of $45–$50 million, implying roughly 35% to 50% growth.
Higher spending on sales, marketing, and product development drove an adjusted EBITDA loss of $1.3 million and a net loss of $1.6 million in the quarter. Operating expenses rose to $6.7 million, or 76% of revenue, as the company adds distribution capacity, enhances its AI-powered eDIYBS platform, and develops new offerings such as a Three-Year Rate Stabilization Program. A recent PIPE financing provided about $7 million in gross proceeds, leaving cash and equivalents at $10.3 million.
Health In Tech, Inc. presents an investor update highlighting its AI-powered marketplace that helps small and mid-sized employers access self-funded health plans paired with stop-loss insurance, while taking no plan or underwriting risk itself. The business earns recurring administrative fees and a share of stop-loss premiums.
Revenue grew from $19.5 million in 2024 to $33.3 million in 2025, with 2026 revenue guidance of $45–$50 million. First-quarter 2026 revenue rose to $8.8 million from $8.0 million, though Adjusted EBITDA shifted to a $(1.3) million loss as the company increases sales and marketing spending to drive future growth.
As of March 31, 2026, Health In Tech reported $10.3 million in cash and cash equivalents, $15.0 million in working capital and $21.6 million in stockholders’ equity. Business activity included $82.0 million of platform placed plan value, $22.9 million of contracted revenue for the remainder of 2026 and relationships with 896 brokers, third-party administrators and agencies.
Health In Tech, Inc. reported first quarter 2026 revenue of $8.8 million, up from $8.0 million a year earlier, driven mainly by higher fees revenue. The company posted a net loss of $1.6 million, compared with net income of $0.5 million in the prior-year quarter, as operating expenses rose sharply.
Adjusted EBITDA was a loss of $1.3 million versus positive $1.2 million a year ago. Management reiterated full-year 2026 revenue guidance of $45–$50 million, implying approximately 35% to 50% growth, supported by $22.9 million of contracted revenue as of March 31, 2026. A March 2026 private investment in public equity provided about $7.0 million in gross proceeds, lifting cash and cash equivalents to $10.3 million at quarter end.
Health In Tech, Inc. reported that Dustin Plantholt will depart from his role as Chief AI & Marketing Officer, effective April 30, 2026. The company states this change is part of a business transition and not due to any disagreement over operations, policies, or practices.
HITChain Inc., a subsidiary, entered into a Consulting Agreement dated May 1, 2026 with Plantholt Advisory Group LLC, owned and controlled by Mr. Plantholt. Under this arrangement, the consultant will receive monthly compensation and Mr. Plantholt will be granted 500,000 restricted shares of HITChain common stock, vesting in equal monthly installments over 12 months, subject to continued service. Either party may terminate the agreement with ten days’ prior written notice.
Health In Tech, Inc. is registering 5,600,000 shares of Class A Common Stock for resale by selling stockholders under a shelf registration. The resale shares were issued in a PIPE and the company will receive no proceeds from secondary sales.
The registration covers shares issued in the PIPE Offering that closed on March 27, 2026 and is being filed pursuant to the related Registration Rights Agreement. The prospectus lists plan of distribution options and states shares may be sold on Nasdaq (symbol HIT) or by other permitted methods.
Health In Tech, Inc. director and Chief Executive Officer Tim Donald Johnson reported a tax-related share disposition. On April 15, 2026, he surrendered 35,140 shares of Class A Common Stock at $1.50 per share to cover withholding and remittance obligations triggered by the vesting of restricted stock.
After this tax-withholding disposition, he directly holds 23,514,601 Class A shares, consisting of 1,079,624 restricted and 22,434,977 unrestricted Class A shares, and this figure excludes 9,000,000 Class B shares and 734,707 stock options.
Health In Tech, Inc. Chief Growth Officer Hasan Zain Syed surrendered 3,448 shares of Class A Common Stock at a price of $1.50 per share to the company to cover tax withholding on vested restricted stock. Following this tax-withholding disposition, he directly holds 216,552 Class A shares, including 211,552 restricted shares and 5,000 unrestricted shares.
Health In Tech, Inc. director and Chief Financial Officer Qian LinLin reported a routine tax-related share disposition. On the vesting of previously granted restricted Class A Common Stock, 21,480 shares were surrendered to the company at $1.50 per share to satisfy tax withholding and remittance obligations, rather than sold on the open market.
After this tax-withholding disposition, LinLin directly holds 9,107,075 shares of Class A Common Stock, consisting of 1,086,284 restricted shares and 8,020,791 unrestricted shares, while separately excluding 2,700,000 shares of Class B Common Stock and 711,510 options to purchase Class A Common Stock.
Health In Tech, Inc. Chief Executive Officer and 10% owner Johnson Tim Donald reported a compensation-related share transaction. On the vesting of restricted Class A Common Stock, he surrendered 35,140 shares at $1.50 per share to the company to satisfy tax withholding obligations. This Form 4 characterizes the move as a tax-withholding disposition, not an open-market sale, and indicates he continues to hold a substantial direct position in Class A Common Stock after the transaction.